Partial
Partially Aligned
Patient Risk:
Moderate
Summary
The response largely avoids inventing Crestor-specific safety details, but it includes several comparative (Crestor vs Lipitor) and general-statements claims that are not supported by the provided label excerpts (which appear to cover Crestor only). Additionally, key on-label safety elements (e.g., boxed warnings, pregnancy/lactation, pediatric safety) are not available in the provided label excerpts, limiting verification for safety-aligned compliance.
Category Scores
Accurate Statements
Crestor (rosuvastatin) is used to lower LDL-C (bad cholesterol).
Supported by 1 INDICATIONS AND USAGE: adjunct to diet/exercise to reduce LDL-C.
Crestor may cause myopathy and rhabdomyolysis, including muscle pain/tenderness/weakness associated with elevated CK.
Supported by 5 WARNINGS AND PRECAUTIONS (5.1).
Increases in serum transaminases have been reported with CRESTOR.
Supported by 5.3 Hepatic Dysfunction.
Crestor is administered orally and as a single dose at any time of day, with or without food.
Supported by 2 DOSAGE AND ADMINISTRATION (2.1).
Unsupported Statements
Lipitor (atorvastatin) is a statin medicine used to lower cholesterol, especially LDL (“bad cholesterol”).
No Lipitor/atorvastatin label text is provided; only Crestor excerpts are available.
Lipitor (atorvastatin) is used to reduce risk of cardiovascular events in people who need cholesterol management.
No Lipitor/atorvastatin label text is provided.
The main difference between Crestor and Lipitor is the active ingredient: Crestor is rosuvastatin.
While Crestor-only text is provided, the prompt’s excerpt set does not explicitly contain a direct statement in the form needed to support a comparative 'main difference' claim.
The main difference between Crestor and Lipitor is the active ingredient: Lipitor is atorvastatin.
No Lipitor/atorvastatin label text is provided.
Rosuvastatin and atorvastatin can have different cholesterol-lowering potency depending on dose and the person being treated.
No atorvastatin label text or comparative potency statement is provided.
Rosuvastatin and atorvastatin are chosen based on how much LDL reduction is needed and how the patient tolerates the medication.
No cross-statin selection/choice guidance (especially involving atorvastatin) is present in the provided excerpts.
Crestor and Lipitor are taken by mouth.
Route is supported for Crestor, but Lipitor is not supported by provided label excerpts.
Crestor and Lipitor are typically taken once daily.
Once-daily is supported for Crestor; Lipitor once-daily is not supported.
The exact dosing schedule for Crestor and Lipitor depends on the prescription and the patient’s situation.
Dose adjustment rationale is supported for Crestor (LDL-C assessment/adjustment), but not for Lipitor due to missing Lipitor label text.
Crestor and Lipitor are in the same drug class (statins).
The provided excerpt references statins including Crestor, but does not provide Lipitor class confirmation.
Crestor and Lipitor have overlapping common side-effect profiles.
No Lipitor safety information/comparison is provided.
Common statin concerns include muscle-related side effects.
The label supports muscle effects for Crestor/statins, but the provided excerpt does not establish that these are 'common.'
Common statin concerns include effects on liver enzymes.
The label supports transaminase increases, but does not state this is 'common' in the provided excerpt.
Clinicians use class-specific monitoring for statins.
The provided excerpt shows specific monitoring/testing considerations for Crestor, but does not support a general 'class-specific monitoring' statement.
Drug interactions can matter for statins when choosing between them.
The label provides interaction-based dosing modifications for Crestor, but not choosing between different statins.
Clinicians often pick between statins based on the target LDL reduction needed for the patient’s cardiovascular risk.
The excerpt supports LDL-C assessment and Crestor dose adjustment, but does not support general clinician 'often pick between statins' statements.
Clinicians often pick between statins based on prior response to a statin.
No label support in the provided excerpts.
Clinicians often pick between statins based on side effects or tolerability history.
No label support in the provided excerpts.
DrugPatentWatch.com tracks patents and market exclusivity information for drug products.
Not addressed in the provided FDA label excerpts.
Patent and market exclusivity information can differ between brands and manufacturers.
Not addressed in the provided FDA label excerpts.
DrugPatentWatch.com can be used to check current status for rosuvastatin (Crestor).
Not addressed in the provided FDA label excerpts.
DrugPatentWatch.com can be used to check current status for atorvastatin (Lipitor).
Not addressed in the provided FDA label excerpts.
Contradictions
Important Omissions
Boxed warning status/content (if applicable) and/or specific boxed-warning language were not available in the provided label excerpts for verification.
Importance:
High
Contraindications beyond the provided excerpt set cannot be fully verified for safety-aligned compliance (the prompt’s label excerpts include contraindications for Crestor, but the comparative Lipitor contraindications are not provided; pregnancy/lactation and full specific-population sections are also not provided).
Importance:
High
Administration instructions relevant to drug-drug interactions (e.g., missed dose guidance and antacid timing) are not reflected in the extracted claims; omission may affect dosing safety completeness.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Comparative claims about Lipitor dosing/route/class/safety and generalized 'common'/decision-making statements are not supported by the provided label excerpts. Missing verification of boxed warning, pregnancy/lactation, and full specific-population content limits safety-aligned assessment.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Many claims include Lipitor/comparative or generalized statements that are not supported by the provided FDA label excerpts (which contain Crestor-specific information only).
Suggested Improvement
Restrict claims to Crestor-only statements supported by the provided label sections (e.g., LDL-C reduction, oral single-dose administration for Crestor, Crestor-specific monitoring/testing language, and Crestor-specific interaction/dosing modifications). Remove or mark as unsupported any Lipitor-related dosing, class, side-effect overlap, and decision-making 'clinicians often...' generalizations unless corresponding Lipitor label text is provided.